Advisors Preferred LLC Makes New Investment in Genmab A/S Sponsored ADR $GMAB

Advisors Preferred LLC bought a new stake in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 50,720 shares of the company’s stock, valued at approximately $1,361,000.

Several other large investors also recently modified their holdings of the stock. CIBC Private Wealth Group LLC increased its position in shares of Genmab A/S by 291.9% in the fourth quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company’s stock worth $25,000 after purchasing an additional 616 shares during the period. NewEdge Advisors LLC raised its stake in Genmab A/S by 1,229.0% in the third quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock valued at $38,000 after purchasing an additional 1,143 shares in the last quarter. V Square Quantitative Management LLC bought a new stake in Genmab A/S during the first quarter worth about $34,000. Brown Brothers Harriman & Co. lifted its position in Genmab A/S by 143.4% during the third quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock worth $41,000 after purchasing an additional 780 shares during the period. Finally, Founders Capital Management grew its stake in Genmab A/S by 40.0% during the fourth quarter. Founders Capital Management now owns 1,400 shares of the company’s stock worth $43,000 after buying an additional 400 shares in the last quarter. 7.07% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on GMAB. BNP Paribas Exane raised shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, April 22nd. The Goldman Sachs Group raised shares of Genmab A/S from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 22nd. Wolfe Research assumed coverage on shares of Genmab A/S in a research report on Friday, March 27th. They issued an “outperform” rating and a $32.00 target price on the stock. Truist Financial started coverage on shares of Genmab A/S in a research note on Wednesday, May 27th. They set a “buy” rating and a $40.00 target price on the stock. Finally, HC Wainwright upped their price target on shares of Genmab A/S from $38.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, July 2nd. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $38.21.

Genmab A/S Trading Down 0.2%

NASDAQ GMAB opened at $28.73 on Wednesday. The firm has a market capitalization of $17.91 billion, a PE ratio of 21.77, a price-to-earnings-growth ratio of 1.88 and a beta of 0.84. The business’s 50-day moving average price is $26.51 and its two-hundred day moving average price is $28.48. The company has a current ratio of 2.18, a quick ratio of 2.17 and a debt-to-equity ratio of 0.87. Genmab A/S Sponsored ADR has a 12 month low of $21.00 and a 12 month high of $35.43.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.